Viatris (LTS:0A5V) Beginning Cash Position : $994 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Viatris Beginning Cash Position?

Viatris's Beginning Cash Position for the quarter that ended in Mar. 2024 was $994 Mil.

Viatris's quarterly Beginning Cash Position increased from Sep. 2023 ($631 Mil) to Dec. 2023 ($1,312 Mil) but then declined from Dec. 2023 ($1,312 Mil) to Mar. 2024 ($994 Mil).

Viatris's annual Beginning Cash Position declined from Dec. 2021 ($850 Mil) to Dec. 2022 ($706 Mil) but then increased from Dec. 2022 ($706 Mil) to Dec. 2023 ($1,263 Mil).

Viatris Beginning Cash Position Historical Data

The historical data trend for Viatris's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Beginning Cash Position Chart

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

389.30

491.20

850.00

706.20

1,262.50

Viatris Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															1,262.50	510.70	631.40	1,311.80	993.60

Viatris Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Viatris Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Viatris's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (LTS:0A5V) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (LTS:0A5V) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 1VTRS:Italy VIA:Germany MYL:Austria

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris (LTS:0A5V) Headlines

No Headlines